e-learning
resources
London 2016
Sunday, 04.09.2016
Sarcoidosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Mortality and survival predictor in chronic hypersensitivity pneumonitis
Inigo Ojanguren Arranz (Barcelona, Spain), Inigo Ojanguren Arranz, Ferran Morell, Ana Villar, Christian Romero, María Antonia Ramón, María Jesus Cruz, Xavier Muñoz
Source:
International Congress 2016 – Sarcoidosis
Session:
Sarcoidosis
Session type:
Thematic Poster
Number:
833
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Inigo Ojanguren Arranz (Barcelona, Spain), Inigo Ojanguren Arranz, Ferran Morell, Ana Villar, Christian Romero, María Antonia Ramón, María Jesus Cruz, Xavier Muñoz. Mortality and survival predictor in chronic hypersensitivity pneumonitis. Eur Respir J 2016; 48: Suppl. 60, 833
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Pulmonary sarcoidosis
Definition and history of sarcoidosis
To code or not to code chronic pulmonary aspergillosis associated malnutrition in PMSI database: that is the problem…
Related content which might interest you:
Chronic hypersensitivity pneumonitis: Is the interstitial pneumonias disease behavior classification suitable for outcome stratification?
Source: International Congress 2015 – Interstitial lung diseases II
Year: 2015
Childhood diffuse parenchymal lung diseases: Diagnosis, treatment and outcome
Source: Annual Congress 2013 –Diffuse parenchymal lung disease I
Year: 2013
Risk factors for chronic pulmonary aspergillosis in a low prevalence country and their effect on survival
Source: International Congress 2015 – Immunodepression and severe pneumonia
Year: 2015
A large cohort study of clinical outcomes and prognostic predictors in patients with acute exacerbation of idiopathic pulmonary fibrosis
Source: International Congress 2014 – IPF and surroundings
Year: 2014
Rituximab for the treatment of chronic hypersensitivity pneumonitis
Source: International Congress 2015 – Interstitial lung diseases I
Year: 2015
Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse parenchymal lung disease III
Year: 2013
Chronic hypersensitivity pneumonitis with familial history of interstitial lung disease
Source: Annual Congress 2010 - Pathogenesis of diffuse parenchymal lung disease
Year: 2010
Using the ILD-GAP model to predict mortality in chronic interstitial lung disease
Source: International Congress 2015 – IIPs: orphan
Year: 2015
Chronic interstitial lung disease in children
Source: Eur Respir Rev, 27 (147) 170100; 10.1183/16000617.0100-2017
Year: 2018
Chronic interstitial lung disease in children
Source: International Congress 2017 – Paediatric year in review: update on paediatric pulmonology
Year: 2017
Morality predictors in acute exacerbation of idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 6
Year: 2014
Interstitial lung disease caused by designer drugs
Source: International Congress 2015 – A morphological view of chest pathology
Year: 2015
Variation in mortality from interstitial lung disease by diagnosis
Source: International Congress 2015 – IIPs: orphan
Year: 2015
Desquamative interstitial pneumonia in a Danish cohort, treatment response and outcome
Source: International Congress 2014 – ILDs 2
Year: 2014
Addition of respiratory hospitalizations 24weeks prior to the ILD-GAP model to predict mortality in chronic interstitial lung disease
Source: International Congress 2016 – Clinical aspects of ILD
Year: 2016
Risk factors and treatment outcomes in patients with chronic pulmonary aspergillosis
Source: International Congress 2016 – Severe respiratory infections in the intensive care unit and pleural and fungal infections
Year: 2016
Clinical experience with nintedanib for the treatment of IPF in 80 cases
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
The prognostic factor in patients with myositis-associated interstitial lung disease
Source: International Congress 2014 – ILDs: connective tissue disease
Year: 2014
Burden and impact of hospital-acquired infections in patients with chronic lung disease
Source: International Congress 2016 – Burden of respiratory diseases: from environmental aspects to healthcare consumption
Year: 2016
Primary pulmonary interstitial glycogenosis. Long term outcome
Source: Annual Congress 2013 –Diffuse parenchymal lung disease I
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept